Advancing today’s therapies to enable healthier lives
We are a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases
Proprietary portfolio
Using our Arestat® technology platform, we are developing enhanced therapeutic medicines for the treatment of diabetes and obesity
Partnering
We are partnering with leading pharmaceutical and medtech companies to develop enhanced therapeutic medicines
Validated technology
A business underpinned by the world-leading Arestat® technology platform with a robust intellectual property portfolio
Latest News
-
29th September 2025
Executive and Non-Executive Board Changes
-
25th September 2025
Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 million
-
4th September 2025
Arecor announces positive FDA feedback on Phase 2 clinical study design for AT278 in an AID system